Phospholipases as mediators of amyloid beta peptide neurotoxicity: An early event contributing to neurodegeneration characteristic of Alzheimer's disease

Neuroscience Letters

Volumn 257, Issue 2, 1998, Pages 93-96

  Kanfer, Julian N ^a   Sorrentino, Giuseppe ^b   Sitar, Daniel S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Alzheimer's disease; Amyloid beta peptide; Neurodegeneration; Phospholipase A2; Phospholipase C; Phospholipase D

Indexed keywords

AMYLOID BETA PROTEIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PHOSPHOLIPASE D;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOUSE; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; HUMANS; NERVE DEGENERATION; NEUROTOXINS; PHOSPHOLIPASES;

EID: 0032573453     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00806-4     Document Type: Article

References (27)

1. Bartoo G.T., Nochlin D., Chang D., Kim Y., Sumi S.M. The mean Aβ load in the hippocampus correlates with duration and severity of dementia in subgroups of Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:1997;531-540.
2. Breitner J.C.S. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47:1996;401-411.
3. Chauhan N.B., Lee J.M., Seigel G.J. Na, K-ATPase mRNA levels and plaque load in Alzheimer's disease. J. Mol. Neurosci. 9:1997;151-166.
4. Cox D.A., Cohen M.L. Amyloid β-induced neurotoxicity is associated with phospholipase D activation in cultured rat hippocampal cells. Neurosci. Lett. 229:1997;37-40.
5. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27:1990;457-464.
6. Fagarasan M.O., Efthimiopoulos S. Mechanism of amyloid beta-peptide (1-42) toxicity in PC12 cells. Mol. Psychiatry. 1:1996;398-403.
7. 2 in neurodegeneration. Neurochem. Int. 30:1997;517-522.
8. Fowler C.J. The role of the phosphoinositide signalling system in the pathogenesis of sporadic Alzheimer's disease: a hypothesis. Brain Res. Brain Res. Rev. 25:1997;373-380.
9. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885-890.
10. 2+ signalling in fully differentiated brain cells of adult mice. Amyloid-Int. J. Exp. Clin. Invest. 3:1996;234-241.
11. Ishikawa H., Ozawa H., Saito T., Takahata N., Takemura H. Calcium mobilization evoked by amyloid β-protein involves inositol 1,4,5-triphosphate production in human platelets. Life Sci. 62:1998;705-713.
12. Iversen L.L., Mortshire-Smith R.J., Pollock S.J., Shearman M.S. The toxicity in vitro of β-amyloid protein. Biochem. J. 311:1995;1-16.
13. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
14. Lee P.N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology. 13:1994;131-144.
15. McClure R.J., Kanfer J.N., Panchalingam K., Klunk W.E., Pettegrew J.W. Magnetic resonance spectroscopy and its application to aging and Alzheimer disease. Neuroimaging Clin. N. Am. 5:1995;69-86.
16. McGeer P.L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet. 335:1990;1037.
17. Parnetti L., Tarducci R., Presciutti O., Lowenthal D.T., Pippi M., Palumbo B., Gobbi G., Pelliccioli G.P., Senin U. Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech. Ageing Dev. 97:1997;9-14.
18. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., Cotman C.W. Structure-activity analyses of β-amyloid peptides: contributions of the β 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64:1995;253-265.
19. Selkoe D.J. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17:1994;489-517.
20. Singh I.N., Sato K., Takashima A., Kanfer J.N. Activation of LA-N-2 cell phospholipases by single alanine substitution analogs of amyloid β peptide (25-35). FEBS Lett. 405:1997;65-67.
21. Singh I.N., Sorrentino G., Kanfer J.N. Amyloid beta protein (25-35) activation of phospholipase A2 in LA-N-2 cells. Alzheimers Res. 2:1996;121-128.
22. Singh I.N., Sorrentino G., Kanfer J.N. Amyloid β protein (25-35) stimulation of phospholipase C in LA-N-2 cells. J. Neurochem. 69:1997;252-258.
23. Singh, I.N., Sorrentino, G. and Kanfer, J.N., Activation of LA-N-2 cell phospholipase D by amyloid beta protein (25-35), Neurochem. Res. (1998) in press.
24. 2 and D of LA-N-2 cells. Neurosci. Lett. 222:1997;5-8.
25. Singh I.N., Sorrentino G., Sitar D.S., Kanfer J.N. (-)-Nicotine inhibits the activations of phospholipases A2 and D by amyloid β protein. Brain Res. 800:1998;275-281.
26. Tanzi R.E., Kovacs D.M., Kim T.W., Moir R.D., Guenette S.Y., Wasco W. The gene defects responsible for familial Alzheimer's disease. Neurobiol. Dis. 3:1996;159-168.
27. Zamani M.R., Allen Y.S., Owen G.P., Gray J.A. Nicotine modulates the neurotoxic effect of beta-amyloid (25-35) in hippocampal cultures. NeuroReport. 8:1997;513-517.